Getting a medicine or medical device approved in a new country can involve repeating many of the same regulatory checks that may already have been completed elsewhere. Mexico’s COFEPRIS Reliance Pathway is meant to reduce some of that duplication.
Instead of starting every review from the beginning, COFEPRIS can use regulatory work already completed by certain recognized authorities as part of its own assessment. This does not mean automatic approval in Mexico. The application still goes through COFEPRIS, which makes the final decision on sanitary registration.
Not every medicine or medical device will follow this route. Eligibility depends on the product and the type of prior regulatory approval available. The following sections cover the applicable authorities, required documents and review timelines.
Talk to Our Experts for
What Is the COFEPRIS Reliance Pathway?
The COFEPRIS Reliance Pathway is an abbreviated regulatory procedure for eligible medicines and medical devices seeking sanitary registration in Mexico.
In a reliance review, COFEPRIS may use the evaluation or regulatory decision of a recognized Reference Regulatory Authority as part of its own assessment. Depending on the case, that previous regulatory work may support all or part of the Mexican review.
The process does not transfer regulatory responsibility to the foreign authority. COFEPRIS remains responsible for reviewing the application against Mexican requirements and issuing the final sanitary registration decision.
Regulatory Basis for the COFEPRIS Reliance Pathway
The current COFEPRIS Reliance Pathway is based on an agreement published in Mexico’s Diario Oficial de la Federación on 18 July 2025. The agreement established general rules for using an abbreviated regulatory pathway when COFEPRIS recognizes certain requirements, tests and evaluation procedures carried out by Reference Regulatory Authorities or through the WHO Prequalification Programme.
These guidelines apply to sanitary registration of health products in Mexico and set out how COFEPRIS may use regulatory decisions from recognized authorities as part of its own review. The framework is still active, and COFEPRIS continues to maintain dedicated Reliance guidance for both medicines and medical devices.
Who Can Use the COFEPRIS Abbreviated Reliance Pathway?
The abbreviated Reliance pathway is available for eligible medicines and medical devices seeking sanitary registration in Mexico.
Eligibility depends on the product category and whether the application falls within the conditions set by COFEPRIS for the relevant Reliance or equivalence route.
COFEPRIS Reliance Pathway for Medicines
COFEPRIS allows eligible medicines to be submitted through an abbreviated Reliance route when the application is supported by a qualifying regulatory decision from a recognized Reference Regulatory Authority or an applicable international programme.
For medicines, COFEPRIS maintains a specific equivalence framework and also lists a dedicated procedure for sanitary registration of medicines through equivalence with Reference Regulatory Authorities. The Reliance route is intended to use previous regulatory work as part of the Mexican review while maintaining the requirements needed for sanitary registration in Mexico.
Eligible Medicines
The COFEPRIS abbreviated Reliance route for medicines applies to several medicine categories. The official COFEPRIS procedure COFEPRIS-04-040 lists:
- New molecules
- Generic medicines
- Innovative biotechnological medicines
- Biocomparable biotechnological medicines
- Biological products
- Vaccines
These products may be submitted through the equivalence route when the applicable COFEPRIS conditions are met and the application is supported by a qualifying decision from a recognized Reference Regulatory Authority.
Recognized Regulatory Authorities
For medicines, COFEPRIS recognizes regulatory decisions from ICH founding members or permanent regulatory members and from WHO-Listed Authorities (WLA) that are listed for the function of marketing authorization of medicines.
For generic medicines, COFEPRIS may also use evaluations performed by the World Health Organization through its Prequalification Programme, in addition to the recognized Reference Regulatory Authorities.
The authority or programme relied upon must therefore fall within the categories recognized under the applicable COFEPRIS Reliance or equivalence framework. The current COFEPRIS Reliance page continues to link medicine applications to the official equivalence framework and CTD requirements.
Requirements for Medicine Registration
As part of the medicine approval process in Mexico, medicines submitted through the COFEPRIS equivalence or Reliance route must include the documentation required under COFEPRIS-04-040.
The official procedure requires, among other items:
- prescribing information in its full and reduced versions;
- a manufacturing licence, certificate or equivalent document;
- patent information where applicable;
- a certificate of free sale or equivalent;
- proposed labels and package insert;
- proof of legal representation;
- a Good Manufacturing Practices certificate or equivalent;
- technical and scientific information in the Common Technical Document (CTD), including quality, preclinical and clinical information; and
- the relevant marketing authorization or equivalent document from the Reference Regulatory Authority used for the equivalence application.
COFEPRIS also states that the CTD should be used to organize the medicine registration dossier, and its current guidance follows the internationally aligned M4 structure for quality, safety and efficacy information.
For applications based on an earlier authorization from a Reference Regulatory Authority, COFEPRIS may require authority-specific evidence. For example, the official procedure identifies documents such as an FDA approval letter, an EMA marketing authorization, or equivalent evidence from other recognized authorities, depending on the route used.
COFEPRIS Reliance Pathway for Medical Devices
COFEPRIS also allows eligible medical devices to use an abbreviated Reliance route for sanitary registration in Mexico. The current COFEPRIS framework specifically covers medical devices and links the process to the equivalence agreements and the abbreviated Reliance pathway.
For medical devices, COFEPRIS maintains a dedicated procedure for sanitary registration by equivalence of Reference Regulatory Authorities, identified as COFEPRIS-04-050. The agency also publishes a specific requirements guide for medical device applications submitted through equivalence agreements and the Reliance pathway.
Eligible Medical Devices
The COFEPRIS Reliance or equivalence route can be used for medical devices that already have an approval from a regulatory authority recognized by COFEPRIS.
The official COFEPRIS-04-050 procedure covers medical devices such as:
- medical equipment;
- prostheses and orthoses;
- functional aids;
- diagnostic agents;
- dental-use supplies;
- surgical materials;
- wound-care materials; and
- hygiene products.
Eligibility also depends on the device classification and the authority that granted the earlier approval. For example, the current COFEPRIS procedure specifically identifies certain FDA-, Health Canada- and Japan-approved device classes under the applicable equivalence agreements.
Recognized Regulatory Authorities and Equivalence
For medical devices, the 2025 COFEPRIS Reliance guidelines recognize regulatory decisions from Reference Regulatory Authorities in countries represented on the Management Committee of the International Medical Device Regulators Forum (IMDRF).
The guidelines also recognize Good Manufacturing Practices certificates issued through full members of the Medical Device Single Audit Program (MDSAP). This recognition relates specifically to GMP certification and should not be treated as a general medical device approval route.
COFEPRIS currently maintains a dedicated medical device registration procedure by equivalence, COFEPRIS-04-050, along with a requirements guide covering medical device registrations submitted through equivalence agreements and the Reliance pathway.
Medical Device Registration Requirements
For medical devices submitted through the COFEPRIS equivalence or Reliance route, the application must include the documents required under COFEPRIS-04-050. These include:
- proof of legal representation;
- proof of payment of the applicable fee;
- introductory descriptive information on the device, including its commercial name, generic name, intended use, specifications, sterilization method where applicable, and models or presentations;
- proposed labelling in Spanish;
- instructions for use or an operating manual, where applicable;
- a Certificate of Free Sale or equivalent document; and
- the medical device authorization issued by the Reference Regulatory Authority used for the equivalence application.
COFEPRIS also requires documents submitted in another language to be accompanied by a Spanish translation. Documents issued by foreign authorities may also need to be apostilled or legalized in accordance with the applicable Mexican requirements.
Additional evidence can vary according to the equivalence route and the authority that previously approved the device. For example, applications relying on FDA, Health Canada or Japanese approvals have authority-specific supporting-document requirements under the applicable agreements.
COFEPRIS Reliance Pathway Approval Timelines
The 2025 COFEPRIS Reliance guidelines set specific maximum review periods for applications submitted through the equivalence route:
| Product | Maximum COFEPRIS resolution time |
| Medicines | 45 working days |
| Medical devices | 30 working days |
Article 37 of the official guidelines sets a maximum of 45 working days for medicine registration applications submitted by equivalence with Reference Regulatory Authorities. Article 38 sets a maximum of 30 working days for medical device applications under the same framework.
These timelines apply specifically to applications using the Reliance/equivalence pathway and should not be confused with the timelines for standard COFEPRIS registration procedures, which follow separate rules.
COFEPRIS Reliance vs Standard Regulatory Pathway
The main difference between the COFEPRIS Reliance pathway and a standard registration route is how much previous regulatory work can be used during the Mexican review.
Under the Reliance pathway, COFEPRIS may base its decision wholly or partly on evaluations or regulatory decisions already made by a recognized Reference Regulatory Authority. The 2025 guidelines define this as an abbreviated regulatory procedure that uses regulatory work from another jurisdiction to support the Mexican decision.
A standard registration procedure does not depend on an eligible foreign regulatory decision in the same way. The application is assessed under the ordinary Mexican registration requirements applicable to the product category.
Importantly, a Reliance-based registration has the same legal effect in Mexico as a sanitary registration granted through an ordinary procedure. COFEPRIS still remains responsible for the final regulatory decision.
| Aspect | Reliance pathway | Standard pathway |
| Previous foreign regulatory assessment | Used where the applicable COFEPRIS conditions are met |
Not the basis of the ordinary review
|
| Review approach | Abbreviated; may rely wholly or partly on prior regulatory work |
Conducted under the ordinary Mexican registration procedure
|
| Final decision | Made by COFEPRIS | Made by COFEPRIS |
| Legal effect of registration | Same legal effect as an ordinary sanitary registration |
Ordinary sanitary registration
|
Benefits of the COFEPRIS Reliance Pathway
For eligible medicines and medical devices, the COFEPRIS Reliance Pathway can make the registration process in Mexico more efficient.
COFEPRIS can use regulatory work already completed by a recognized Reference Regulatory Authority when reviewing the application. This can avoid repeating parts of the same assessment and may help reduce the time needed for review.
The pathway is also intended to support earlier access to the Mexican market while the usual requirements for product quality, safety and efficacy continue to apply.
Key Considerations for Companies Seeking Market Approval in Mexico
Before using the COFEPRIS Reliance pathway, companies should check whether the product and its earlier regulatory approval fit the relevant Reliance or equivalence route. The documents required will vary depending on whether the application is for a medicine or a medical device.
The Mexican dossier still needs to meet the applicable COFEPRIS requirements. For medicines, COFEPRIS currently provides the CTD Version 3.0 and supporting checklists for sanitary registration applications. For medical devices, a separate requirements guide is available for applications filed through equivalence agreements and the Reliance pathway.
Requirements and supporting guidance can change, so it is important to check the latest COFEPRIS information before preparing a submission.
Companies entering the Mexican market may also need to look at other local compliance requirements, including the COFEPRIS Notice of Operation, depending on the activities carried out in Mexico.
Conclusion
The COFEPRIS Reliance Pathway gives eligible medicines and medical devices another route for registration in Mexico when suitable prior regulatory approvals are available.
It does not replace the Mexican registration process. COFEPRIS still reviews the application and decides whether sanitary registration can be granted.
Before filing, companies should check which Reliance or equivalence route applies, confirm the documents needed and use the latest COFEPRIS guidance.
Need support with COFEPRIS compliance in Mexico? Explore Artixio’s COFEPRIS regulatory services in Mexico for support with registration, market entry and ongoing compliance.
FAQs
1. What is the COFEPRIS Reliance Pathway?
The COFEPRIS Reliance Pathway is an abbreviated evaluation procedure for eligible medicines and medical devices. It allows COFEPRIS to use assessments already carried out by recognized Reference Regulatory Authorities when deciding whether to grant sanitary registration in Mexico.
2. Which products can use the COFEPRIS abbreviated pathway?
The pathway covers medicines and medical devices. For medicines, COFEPRIS-04-040 includes new molecules, generics, innovative and biocomparable biotechnology products, biological products and vaccines. Medical devices are handled through the dedicated equivalence procedure COFEPRIS-04-050.
3. Does FDA approval automatically qualify a product for COFEPRIS approval?
No. FDA approval may support an application where the relevant COFEPRIS equivalence or Reliance requirements are met, but the product must still obtain sanitary registration in Mexico. COFEPRIS performs its own focused review and issues the final decision.
4. How long does the COFEPRIS Reliance pathway take?
The official COFEPRIS medicine equivalence procedure lists a response time of 45 working days. Under the Reliance framework, medical device applications submitted through the applicable equivalence procedure have a maximum review period of 30 working days.
5. Is the COFEPRIS Reliance pathway available for medical devices?
Yes. COFEPRIS has a dedicated medical device registration pathway in Mexico for applications based on equivalence with Reference Regulatory Authorities, identified as COFEPRIS-04-050. COFEPRIS also publishes a specific Reliance/equivalence requirements guide for medical devices.
6. What documents are required for medicine registration through Reliance?
The requirements depend on the medicine and the Reference Regulatory Authority being relied upon. COFEPRIS-04-040 requires a CTD-based dossier together with documents such as the applicable marketing authorization or equivalent, Certificate of Free Sale, GMP evidence, labelling information and other supporting documents required for the product.
